The action of a novel cardiotonic agent N-hydroxy-5,6-dimethoxy-benzo [b] 
T he positive inotropic effects of cardiotonic agents are achieved by increases in intracellular Ca`+ mobilization, by alteration of responsiveness of myofilaments to Ca2, or by a combination of the two mechanisms. 1 The major classes of inotropic agents that are currently used for the treatment of heart failure act through the first mechanism. The cardiac glycosides increase [Ca2"]i through the intracellular Na+ accumulation produced by inhibition of Na+, K'-ATPase and the Na+-Ca2`exchange system.2 Catecholamines (through ,3-adrenoceptor stimulation) and cAMP phosphodiesterase (PDE) inhibitors cause an accumulation of cAMP, which produces phosphorylation of functional proteins such as L-type Ca2`channel proteins, phospholamban, and troponin I via activation of protein kinase A. 
Materials and Methods Isolated Canine Right Ventricular Trabeculae
Hearts were excised from mongrel dogs of either sex (8-10 kg) anesthetized with sodium pentobarbital (30 mg/kg i.v.). Free-running trabeculae (approximately 1 mm in diameter) were dissected from the wall of the right ventricle. Muscles were mounted in 20-ml organ baths containing Krebs-Henseleit solution. The composition of the solution was as follows (mM): NaCI 118, KCI 4.7, CaCI2 2.5, MgSO4 1.2, NaHCO3 24.9, and glucose 11.1 (with 0.057 mM ascorbic acid and 0.027 mM disodium EDTA added to prevent autoxidation of the compounds examined). The solution was bubbled with 95% 02-5% CO2 (pH 7.4). The preparation used was identical to that described previously.22 The maximum force developed by this preparation, approximately 20 mN/mm2, was comparable to that observed in rabbit, rat, and guinea pig22 and in the blood-perfused canine papillary muscle23 when measured at similar temperatures and heart rates. In most preparations, after an equilibration period of 1 hour, the resting and developed tension of the muscle was stable during the course of experiments for many hours. Preparations in which the resting tension increased progressively during the equilibration period were discarded. The pharmacological response to sympathomimetic amines of the present preparation was also similar to that of the blood-perfused canine papillary muscle. 23 These pieces of experimental evidence indicate that the isolated canine right ventricular trabeculae provide an experimental preparation suitable for the pharmacological analysis of the mechanism of newly developed cardiotonic agents.
Determination ofAequorin Light Signals
The Ca 2k-sensitive bioluminescent protein aequorin (prepared for injection according to Blinks et a124 in 1978) was microinjected into the cells of the muscle mounted horizontally in an organ bath constructed for aequorin injection. Bicarbonate-buffered Krebs-Henseleit solution freshly oxygenated with 95% 02-5% CO2 was circulated rapidly past the surface of the muscle at 32°C (the composition of the solution was the same as described above). The muscle was stimulated at a frequency of 0.33 Hz with threshold pulses delivered through punctate electrodes and was stretched to a length at which the contractile force was nearly maximum. After an equilibration period of approximately 30 minutes, electrical stimulation was discontinued, and aequorin microinjection was started. Although it took several hours to complete the microinjection of aequorin, the injection procedure only slightly affected the basal developed force. In the preliminary experiments, it was confirmed that the developed force before starting microinjection (6.98±0.83 mN/mm2) was not significantly different from that after completion of the microinjection (6.73±0.89 mN/mm2, n=5 each). After microinjection, we took maximal care to keep the injected cells quiescent; therefore, the muscle preparations were electrically stimulated only for a short duration before transfer to the experimental organ bath.
Aequorin was dissolved at a concentration of approximately 2 mg/ml in a solution containing 150 mM KCl and 5 mM HEPES buffer, pH 7.5. The solution was loaded into fine-tipped (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) Mfl in 150 mM KCl) micropipettes through which membrane potential was monitored to determine when cells had been penetrated. Aequorin was injected by the application of gas pressure. 24 [24] [25] [26] [27] The maximum inotropic effect of Org 30029 was 140.4+14.6% of that of isoproterenol, and the maximum increase in the amplitude of the Ca21 transients was 15.5 +2.0% (n =5). The force increased further when 10-3 M Org 30029 was applied, and the amplitude of Ca21 transients reached a maximum at 3 x 10-4 M. The concentration-response curve for the isoproterenol-induced inotropic response in this series of experiments was slightly shifted to the right compared with the curve determined in the absence of bupranolol,30 since it is difficult to completely wash out a potent 83-adrenoceptor blocking agent such as bupranolol. 
Influence of Carbachol on the Effects of Org 30029
It has been shown in mammalian ventricular myocardium that the muscarinic receptor activation selectively inhibits the positive inotropic effects associated with accumulation of cAMP metabolism, whereas it scarcely affects the cAMP-independent inotropism such as basal force of contraction and the effects of elevation of In the presence of carbachol, the concentrationresponse curve for the positive inotropic effect of Org 30029 was shifted to the right, and the maximum response was depressed (Figure 7 ). The EC50 of Org 30029 was increased slightly but significantly by carbachol, from the control value of (3.76+0.40)x 10-4 M to (5.79+0.45)x10-' M (n=8). However, the maximum inotropic effect of Org 30029 was 120% of that induced by isoproterenol in the presence of carbachol. The basal force of contraction was 6.65+1.25 mN/mm2 (n=10). Isoproterenol (10-6 M) 41 have been found to affect myocardial contractility by the mechanism subsequent to an increase in Ca24 mobilization. Org 30029 belongs to this class of agents. These drugs have potential importance in the treatment of heart failure from several points of view. They may have less arrhythmogenic action than drugs that act primarily through an increase in intracellular Ca24 mobilization. There is also the possibility that the energy required for the intracellular mobilization of a larger amount of Ca24 would not be needed. This is borne out by the finding that pimobendan, which also increases myofilament Ca24 responsiveness,13-15 results in a smaller increase in heat production for a given increase in developed force than does the 13-adrenoceptor agonist isoproterenol.46 Furthermore, moderate reduction of the afterload to the heart produced by vasodilation mediated through cAMP accumulation in vascular smooth muscle may be beneficial for heart failure patients.
The extent of the contribution of the Ca2' responsiveness and PDE inhibitory action appears to vary markedly among these different agents. The former mechanism is more pronounced in EMD 53998 than in pimobendan. 41 The observation that the positive chronotropic effect of Org 30029 in rabbit and guinea pig right atria is much less pronounced than that of milrinone implies that the contribution of the PDE inhibitory action to the effect of Org 30029 may be relatively less. It has been shown that Org 30029 elicits a negative chronotropic effect in guinea pig right atria,20 in cona wide range of concentrations is shifted to the left and trast to milrinone. 20-50%.18 In conclusion, Org 30029 is a unique cardiotonic agent that may produce a positive inotropic action mainly by increasing the Ca2+ responsiveness of the contractile proteins in intact myocardial cells. Novel cardiotonic agents belonging to this class may be worthy for evaluation of their effectiveness as potential therapeutic drugs for the treatment of congestive heart failure.
